Half-life

0.2 h

Tmax

0.25 h

Category

peptide

Also known as: grf-1-29

Sermorelin is the synthetic 1-29 amino-acid fragment of endogenous growth-hormone-releasing hormone (GHRH). It retains full GHRH receptor activity but has a very short plasma half-life of approximately 12 minutes due to rapid DPP-IV cleavage. It was formerly approved for diagnostic testing of GH reserve and has been used off-label for GH pulse stimulation. The very short half-life means it must be dosed with careful timing relative to meals. Sermorelin is a foundational compound in many GH peptide protocols and is frequently tracked alongside GH secretagogues.

Mechanism

A GHRH analog corresponding to GHRH(1-29). It stimulates the GHRH receptor to promote endogenous, pulsatile growth-hormone release. It has a short duration of action relative to modified analogs.

Research summary

Historically used as a diagnostic agent for growth-hormone secretion and studied in growth-hormone-related contexts. A branded product was previously marketed; availability and regulatory status have changed over time. Long-term outcome data for non-diagnostic uses are limited.

Reported side effects

Reported effects include injection-site reactions, flushing, and headache. Effects on growth hormone and IGF-1 warrant monitoring in a clinical context. This is not a complete safety profile.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

Sermorelin GHRH analog clinical pharmacology · peer-reviewed endocrinology journals (2000)search PubMed for sermorelin growth hormone
Sermorelin product / regulatory history · FDA / regulatory records (2008)branded availability has changed over time; verify current status

References

Sermorelin pharmacokineticsDOI: 10.1210/jcem-71-6-1581

TrackPep er en app til registrering. Den registrerer det, du indtaster, og anbefaler eller beregner aldrig mængder.